Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

7 Big Biotech Stocks to Watch

By Chris Lau, InvestorPlace Contributor

Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.

The Snap Stock Rally Is Stalled — Not Over

By Chris Lau, InvestorPlace Contributor

Snapchat stock paused from its year-long rally, but the user and revenue growth is set to continue so don't panic sell yet.

CGC Stock Looks Like a Buy on the Dip as Stock Falters on Vape Worries

By Chris Lau, InvestorPlace Contributor

Cannabis stocks are in a bear phase and it is taking CGC stock down with it. Beyond next year, profits are around the corner.

General Electric Stock Is Set to Continue Its Rebound

By Chris Lau, InvestorPlace Contributor

General Electric stock trended lower recently but is starting to bring in bulls again. The strong CEO leadership is apparent in reviving GE.

A New CEO is One Reason Why Rite Aid’s Long-Term Prospects are Improving

By Chris Lau, InvestorPlace Contributor

Rite Aid stock has a chance of recovering but the new CEO has plenty of work ahead. The company must grow prescription volumes and sales.

Load More